Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

Zakiya Rice
Melinda Gooderham
Mark G. Lebwohl
Eric L. Simpson
Mark Boguniewicz
Andreas Wollenberg
Irina Lazariciu
Gary L. Chan
Justine Alderfer
Melissa Watkins

Keywords

Abrocitinib, JAK1 inhibitor, Moderate-to-Severe Atopic Dermatitis, Short-Term Efficacy, Disease Severity

References

1. Simpson et al. J Am Acad Dermatol. 2016;74:491-498.

2. Simpson et al. JAMA Dermatol. 2018;154:903-912.

3. Cibinqo (abrocitinib). Prescribing information. Pfizer Ltd.; September 2021.

4. Cibinqo (abrocitinib). Summary of Product Characteristics. Pfizer Europe; October 2022.

5. Cibinqo (abrocitinib). Prescribing information. Pfizer Labs; January 2022.

6. Simpson EL et al. Lancet. 2020;396:255-266.

7. Silverberg JI et al. JAMA Dermatol. 2020;156:863-873.

8. Bieber T et al. N Engl J Med. 2021;384:1101-1112.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.154

Article Details

How to Cite
Rice, Z., Gooderham, M., Lebwohl, M. G., Simpson, E. L. ., Boguniewicz, M., Wollenberg, A., Lazariciu, I., Chan, G. L., Alderfer, J., & Watkins, M. (2023). Short-Term Efficacy and Safety of Abrocitinib by Baseline Disease Severity in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(2), s154. https://doi.org/10.25251/skin.7.supp.154
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 > >>